In the WHO classification, patients with MYC and BCL6 rearrangements are classified as a subtype of DLBCL or as HGBCL NOS, depending on their morphology, while the ICC has created a new provisional entity for these patients (HBGBL-DH-BCL6). The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.